HCPro, JustCoding Outpatient - 2016 Issue 16 (April)
CMS surprises with Part B drug payment model that puts the onus on providers
April 26th, 2016
Subscribe or sign in to view the full article.
Article Overview
This article explains CMS’s proposed Part B drug payment test model and evaluates the broader policy issues it raises for providers and beneficiaries. It discusses the model’s phased structure, the concerns it raises about provider behavior, the possible effects on different provider types and specialties, and why stakeholders are encouraged to submit comments. The piece is relevant to organizations that bill Part B drugs, participate in other CMS payment initiatives, or want to understand how the proposal could affect access, costs, and administrative burden.
Why This Topic Matters
The proposal could affect reimbursement and care delivery for a wide range of Part B drug providers, especially those with high-cost drug acquisition and handling expenses. Understanding the article helps stakeholders assess potential financial, operational, and patient-access implications before responding to CMS.
Article Sections
-
Overview of the proposed Part B drug payment model
Introduces CMS’s proposed test model and the basic structure of the payment changes being discussed. It frames the broader policy debate around the purpose and scope of the initiative.
-
Concerns about assumptions and impacts
Reviews the article’s discussion of provider behavior, therapeutic alternatives, and the potential for unintended effects on different provider groups. It also addresses concerns about how the proposal may affect access, safety, and financial viability.
-
Competing priorities and interaction with other CMS models
Summarizes how the proposal may intersect with other ongoing payment demonstrations and policy changes. It highlights the challenge of interpreting results when multiple initiatives are occurring at once.
-
Share your thoughts with CMS
Covers the article’s call for stakeholders to review the proposal and submit comments. It emphasizes the types of organizational feedback CMS is seeking and the importance of participation in the rulemaking process.
What You Will Learn
- How CMS’s proposed drug payment test model is structured at a high level
- Which provider groups and service lines may be affected differently
- Why stakeholders are concerned about unintended consequences and data interpretation
- How the proposal may interact with other CMS payment initiatives
- What kinds of feedback providers are encouraged to submit to CMS
Who Should Read This
- Hospital and physician practice administrators
- Oncology and specialty provider organizations
- Revenue cycle and reimbursement professionals
- Medical coders and billing staff working with Part B drugs
- Healthcare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com